Dianthus Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Dianthus Therapeutics
DNTH Stock   49.21  1.81  3.82%   
Dianthus Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Dianthus Therapeutics' valuation are provided below:
Gross Profit
3.1 M
Market Capitalization
2 B
Enterprise Value Revenue
535.654
Revenue
3.1 M
Earnings Share
(3.50)
We have found one hundred twenty available fundamental signals for Dianthus Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Traders should compare all of Dianthus Therapeutics prevailing fundamentals against the fundamentals between 2010 and 2026 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to about 58.6 M. The Dianthus Therapeutics' current Enterprise Value is estimated to increase to about (85.4 M)

Dianthus Therapeutics Total Revenue

4.66 Million

Check Dianthus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Dianthus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 450.1 K, Interest Expense of 2.7 M or Selling General Administrative of 16.3 M, as well as many indicators such as Price To Sales Ratio of 83.61, Dividend Yield of 0.0 or PTB Ratio of 2.25. Dianthus financial statements analysis is a perfect complement when working with Dianthus Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Dianthus Stock
Check out the analysis of Dianthus Therapeutics Correlation against competitors.
For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.

Dianthus Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets451.6 M430.1 M136.6 M
Slightly volatile
Other Current Liabilities7.9 M15 M5.4 M
Slightly volatile
Total Current Liabilities10.9 M21.2 M8 M
Slightly volatile
Total Stockholder Equity425.6 M405.3 M126.1 M
Slightly volatile
Property Plant And Equipment Net3.1 M1.6 M2.5 M
Slightly volatile
Accounts Payable2.8 M5.3 M2.4 M
Slightly volatile
Cash24.9 M26.2 M36.4 M
Slightly volatile
Non Current Assets Total112.4 M107.1 M21.4 M
Slightly volatile
Cash And Short Term Investments332.4 M316.5 M110 M
Slightly volatile
Net Receivables690 K726.3 K3.5 M
Slightly volatile
Common Stock Shares Outstanding40.2 M38.3 M8.8 M
Slightly volatile
Liabilities And Stockholders Equity451.6 M430.1 M136.6 M
Slightly volatile
Other Current Assets2.8 M5.6 M1.9 M
Slightly volatile
Other Stockholder Equity636 M605.7 M206.1 M
Slightly volatile
Total Liabilities14 M24.8 M9.9 M
Slightly volatile
Total Current Assets339.2 M323 M115.2 M
Slightly volatile
Common Stock36.2 K35.6 K22.7 K
Slightly volatile
Other Assets146.1 K139.2 K43.4 K
Slightly volatile
Short Term Investments304.8 M290.3 M113.2 M
Slightly volatile
Non Current Liabilities Total2.9 M2.8 M2.4 M
Slightly volatile
Inventory613.8 K979.8 K430.4 K
Slightly volatile
Property Plant And Equipment Gross2.3 M2.2 M517.2 K
Slightly volatile
Net Working Capital316.9 M301.8 M68.9 M
Slightly volatile
Property Plant Equipment1.2 M1.1 M324.6 K
Slightly volatile
Short and Long Term Debt Total1.1 M1.7 M887.3 K
Slightly volatile
Other Liabilities632.8 K711.9 K777 K
Slightly volatile
Current Deferred Revenue578.4 K550.9 K177 K
Slightly volatile
Short Term Debt289.9 K288 K345 K
Slightly volatile

Dianthus Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization450.1 K473.8 K527.8 K
Slightly volatile
Interest Expense2.7 M4.1 M2.2 M
Slightly volatile
Selling General Administrative16.3 M28.7 M11.7 M
Slightly volatile
Selling And Marketing Expenses443.3 K408.2 K251.4 K
Slightly volatile
Other Operating Expenses130.5 M124.3 M46.3 M
Slightly volatile
Research Development100.3 M95.6 M33.5 M
Slightly volatile
Cost Of Revenue450.1 K473.8 K527.8 K
Slightly volatile
Total Operating Expenses130.5 M124.3 M46 M
Slightly volatile
Net Interest Income21 M20 M3.7 M
Slightly volatile
Interest Income21 M20 M3.7 M
Slightly volatile
Total Revenue4.7 M7.2 M2.6 M
Slightly volatile

Dianthus Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation15.6 M14.8 M5 M
Slightly volatile
Begin Period Cash Flow159.9 M152.2 M41.7 M
Slightly volatile
Depreciation450.1 K473.8 K527.8 K
Slightly volatile
Capital Expenditures89.8 K94.5 K947.4 K
Very volatile
Total Cash From Financing Activities308.7 M294 M93.9 M
Slightly volatile
End Period Cash Flow25.2 M26.5 M36.4 M
Slightly volatile
Issuance Of Capital Stock325.1 M309.6 M73.9 M
Slightly volatile
Change To Netincome536.2 K1 M298.6 K
Slightly volatile
Change To Liabilities3.2 M2.9 M4.4 M
Slightly volatile
Change To Inventory3.3 M3.7 M4.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio83.61134137
Slightly volatile
PTB Ratio2.252.3724.9529
Slightly volatile
Days Sales Outstanding51.6154.33258
Slightly volatile
Book Value Per Share11.5612.1721.8716
Slightly volatile
Stock Based Compensation To Revenue1.951.860.587
Slightly volatile
Capex To Depreciation0.280.2910.6677
Slightly volatile
PB Ratio2.252.3724.9529
Slightly volatile
Payables Turnover0.810.60.4249
Slightly volatile
Sales General And Administrative To Revenue2.563.611.974
Slightly volatile
Research And Ddevelopement To Revenue7.6212.08.9198
Slightly volatile
Capex To Revenue0.01840.01940.6113
Slightly volatile
Cash Per Share9.039.520.9155
Slightly volatile
Days Payables Outstanding75879842.2 K
Slightly volatile
Income Quality0.650.830.7591
Slightly volatile
Net Debt To EBITDA0.180.191.2639
Pretty Stable
Current Ratio10.2613.79.8638
Slightly volatile
Tangible Book Value Per Share11.5612.1721.8716
Slightly volatile
Receivables Turnover3.946.952.3132
Slightly volatile
Shareholders Equity Per Share11.5612.1721.8716
Slightly volatile
Debt To Equity0.00670.00490.0093
Slightly volatile
Capex Per Share0.00340.00360.4132
Very volatile
Graham Net Net8.348.7819.4104
Slightly volatile
Revenue Per Share0.20.220.4721
Very volatile
Interest Debt Per Share0.04890.05150.3931
Very volatile
Debt To Assets0.00610.00460.0083
Slightly volatile
Operating Cycle51.6154.33258
Slightly volatile
Price Book Value Ratio2.252.3724.9529
Slightly volatile
Days Of Payables Outstanding75879842.2 K
Slightly volatile
Ebt Per Ebit1.050.960.9801
Slightly volatile
Company Equity Multiplier1.231.221.1772
Slightly volatile
Total Debt To Capitalization0.00670.00480.0092
Slightly volatile
Debt Equity Ratio0.00670.00490.0093
Slightly volatile
Quick Ratio10.2613.79.8638
Slightly volatile
Cash Ratio1.061.114.2768
Pretty Stable
Days Of Sales Outstanding51.6154.33258
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.141.151.0477
Slightly volatile
Price To Book Ratio2.252.3724.9529
Slightly volatile
Fixed Asset Turnover2.83.211.3058
Slightly volatile
Debt Ratio0.00610.00460.0083
Slightly volatile
Price Sales Ratio83.61134137
Slightly volatile
Asset Turnover0.03230.01920.015
Slightly volatile
Price Fair Value2.252.3724.9529
Slightly volatile

Dianthus Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap58.6 M61.6 M357 M
Slightly volatile

Dianthus Fundamental Market Drivers

Dianthus Upcoming Events

8th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
8th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Dianthus Therapeutics Financial Statements

Investors use fundamental indicators, such as Dianthus Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Dianthus Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue550.9 K578.4 K
Cost Of Revenue473.8 K450.1 K
Total Revenue7.2 M4.7 M
Stock Based Compensation To Revenue 1.86  1.95 
Sales General And Administrative To Revenue 3.61  2.56 
Research And Ddevelopement To Revenue 12.00  7.62 
Capex To Revenue 0.02  0.02 
Revenue Per Share 0.22  0.20 
Ebit Per Revenue(18.79)(19.73)

Currently Active Assets on Macroaxis

FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
CSANCosan SA ADR
RKTRocket Companies
When determining whether Dianthus Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dianthus Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dianthus Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dianthus Therapeutics Stock:
How To Invest In Dianthus
Details
Is Dianthus Stock a good investment?
Details
What is Dianthus Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Dianthus Therapeutics Correlation against competitors.
For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.
You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is there potential for Biotechnology market expansion? Will Dianthus introduce new products? Factors like these will boost the valuation of Dianthus Therapeutics. Projected growth potential of Dianthus fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Dianthus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.50)
Revenue Per Share
0.085
Quarterly Revenue Growth
(0.82)
Return On Assets
(0.19)
Return On Equity
(0.29)
The market value of Dianthus Therapeutics is measured differently than its book value, which is the value of Dianthus that is recorded on the company's balance sheet. Investors also form their own opinion of Dianthus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dianthus Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Dianthus Therapeutics' market value can be influenced by many factors that don't directly affect Dianthus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between Dianthus Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Dianthus Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Dianthus Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY